We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals
Background: A first-dose of various vaccines provides acceptable protection against infections by SA...
We conducted a registries-based cohort study of long-term care facility residents >65 years of age o...
Background The efficacy of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could...
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary ...
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary ...
Real-world evidence of the vaccine effectiveness (VE) of different COVID-19 vaccines is needed in or...
With the emergence of SARS-CoV-2, influenza surveillance systems in Spain were transformed into a ne...
Introduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using ...
By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain...
Age is among the most prominent risk factors for developing severe COVID-19 disease, and therefore o...
Clinical trials of COVID-19 vaccines currently authorized for emergency use in the United States (Pf...
Background In Finland, both mRNA and adenovirus vector (AdV) Covid-19 vaccines have been used after ...
Observational studies are needed to demonstrate real-world vaccine effectiveness (VE) against severe...
Abstract The rapidity of SARS-CoV-2 vaccination around the world has substantially reduced the numbe...
Background: In the ongoing COVID-19 pandemic, advanced age is a risk factor for a severe clinical co...
Background: A first-dose of various vaccines provides acceptable protection against infections by SA...
We conducted a registries-based cohort study of long-term care facility residents >65 years of age o...
Background The efficacy of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could...
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary ...
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary ...
Real-world evidence of the vaccine effectiveness (VE) of different COVID-19 vaccines is needed in or...
With the emergence of SARS-CoV-2, influenza surveillance systems in Spain were transformed into a ne...
Introduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using ...
By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain...
Age is among the most prominent risk factors for developing severe COVID-19 disease, and therefore o...
Clinical trials of COVID-19 vaccines currently authorized for emergency use in the United States (Pf...
Background In Finland, both mRNA and adenovirus vector (AdV) Covid-19 vaccines have been used after ...
Observational studies are needed to demonstrate real-world vaccine effectiveness (VE) against severe...
Abstract The rapidity of SARS-CoV-2 vaccination around the world has substantially reduced the numbe...
Background: In the ongoing COVID-19 pandemic, advanced age is a risk factor for a severe clinical co...
Background: A first-dose of various vaccines provides acceptable protection against infections by SA...
We conducted a registries-based cohort study of long-term care facility residents >65 years of age o...
Background The efficacy of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could...
Add to ORKG